Results 51 to 60 of about 13,840,459 (217)
Neovascular age-related macular degeneration without drusen in the fellow eye: clinical spectrum and therapeutic outcome [PDF]
, 2016 Wing H Chung,1 Elon H C van Dijk,1 Danial Mohabati,1 Greet Dijkman,1 Suzanne Yzer,2 Eiko K de Jong,3 Sascha Fauser,4 Reinier O Schlingemann,5–7 Carel B Hoyng,3 Camiel J F Boon1,5 1Department of Ophthalmology, Leiden University Medical Center ...
Fauser S +9 more
core +2 more sources
Acta Ophthalmologica, EarlyView.Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car +3 more
wiley +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To determine the relationship between the baseline junctional retinal sensitivity measured with microperimetry and the atrophy progression rate in eyes with geographic atrophy (GA) secondary to age‐related macular degeneration. Methods In this prospective cohort study, patients with GA were examined with fundus autofluorescence (FAF ...
Alexander Kai Thomsen +5 more
wiley +1 more source
, 2010 To assess the interobserver variability (IOV) in indicating retreatment for neovascular Age-related macular degeneration 4 weeks after three Ranibizumab loading doses using spectral domain OCT (SD-OCT) as the primary objective diagnostic ...
Walter, Andreas +12 more
core +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To evaluate real‐world safety experience with aflibercept 8 mg in a large case series of patients with neovascular age‐related macular degeneration (nAMD). Methods Due to a high proportion of patients on short treatment intervals, patients with nAMD at a Danish tertiary retina clinic were systematically switched to aflibercept 8 mg ...
Mary Graciya Karunainathan +12 more
wiley +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To estimate the real‐world incidence of intraocular inflammation (IOI) following intravitreal faricimab injections at a large, highly specialized tertiary centre. Methods Single‐centre, retrospective cohort study with chart review using an electronic injection database and electronic medical records from November 2023 to August 2024 ...
Miklos Schneider +7 more
wiley +1 more source
Patient Reported Outcome Measures in Treatment of Neovascular Age-related Macular Degeneration
, 2021 Neovascular age-related macular degeneration (nAMD) is causing a progressive central vision loss. Intravitreal anti–vascular endothelial growth factor (anti-VEGF) treatment is often effective, but requires frequent injections for years.
Jelin, Elma
core +1 more source
Case Reports in Ophthalmology, 2022 We describe the results of very early pars plana vitrectomy, subretinal r-tPA, and gas tamponade in patients with subretinal macular hemorrhage secondary to neovascular age-related macular degeneration.
Filippo Confalonieri +3 more
doaj +1 more source
Impact of delayed appointments on treatment outcomes in neovascular macular degeneration
Acta Ophthalmologica, EarlyView.Abstract Purpose To evaluate the real‐world visual outcomes of anti‐vascular endothelial growth factor (anti‐VEGF) therapy, the frequency of delayed appointments and the relationship between delays and visual outcomes in patients with neovascular age‐related macular degeneration (nAMD).
Petri Purola +3 more
wiley +1 more source
, 2021 Purpose: To investigate whether qualitative and quantitative features of choroidal neovascular membranes are associated with anti-vascular endothelial growth factor treatment response in patients with neovascular age-related macular ...
Zeydanli, Ece Ozdemir, Gurelik, Gokhan
core +1 more source